search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Effect van verwarmde oxaliplatin op acute perifere neuropathie klachten bij patienten die aanvullend of voor een gevorderde of uitgezaaide darmkanker behandeld worden met oxaliplatin houdende chemotherapie.


- candidate number9299
- NTR NumberNTR2837
- ISRCTNISRCTN wordt niet meer aangevraagd.
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR3-apr-2011
- Secondary IDsNL29016.100.19 / R-09.16A; CCMO / VCMO St. Antonius Ziekenhuis
- Public TitleEffect van verwarmde oxaliplatin op acute perifere neuropathie klachten bij patienten die aanvullend of voor een gevorderde of uitgezaaide darmkanker behandeld worden met oxaliplatin houdende chemotherapie.
- Scientific TitleAcute peripheral neuropathy in patients treated with oxaliplatin: Is it possible to decrease the complaints? (Effect of heated oxaliplatin on acute peripheral neuropathy, a pilot study), September 2009.
- ACRONYMNeuroxa studie
- hypothesisDoes heated oxaliplatin reduce the acute peripheral neuropathy complaints in patient with a colorectal carcinoma.
- Healt Condition(s) or Problem(s) studiedColorectal cancer, Acute peripheral neuropathy, Oxaliplatin induced complaints
- Inclusion criteria1. Patients treated adjuvant or palliative with oxaliplatin for a colon-rectal carcinoma who suffer from an acute peripheral neuropathy after the first treatment with oxaliplatin containing regime;
2. Living within a radius of 30 km from the hospital;
3. Good understanding of the Dutch language.
- Exclusion criteria1. Presence of diabetes mellitus, renal failure, alcoholism, vitamin B 12 deficiency, other neoplasm or HIV;
2. Previous treatment with a neurotoxin cytostatic drug;
3. Already existing peripheral neuropathy.
- mec approval receivedyes
- multicenter trialno
- randomisedno
- groupParallel
- TypeSingle arm
- Studytypeintervention
- planned startdate 15-mrt-2010
- planned closingdate1-mei-2011
- Target number of participants16
- InterventionsOxaliplatin will be heated to a temperature of 36 degrees celsius during the 2-hours infusion period, irrespective the standard prophylaxis with magnesium and calcium.
- Primary outcome1. Decrease of the acute peripheral neuropathy complaints with 1 point or more on the four points scale of the Total Neuropathy Score;
2. Changes in quality of life (cancer related and symptom related) in the period after infusion of heated oxaliplatin in comparison with the period after infusion of oxaliplatin on roomtemperature.
- Secondary outcomeRespons rate by CT scan and changes of CEA (tumormarker).
- Timepoints1. Baseline TNS after course one with oxaliplatin;
2. Just before, 48 hours and one week after two courses with heated oxaliplatin and one course with oxaliplatin on room temperature;
3. CEA, CT scans at baseline, 3 and 6 months after start chemotherapy.
- Trial web siteN/A
- statusopen: patient inclusion
- CONTACT FOR PUBLIC QUERIESDrs. A. Verbeek
- CONTACT for SCIENTIFIC QUERIESDrs. A. Verbeek
- Sponsor/Initiator Sint Antonius Ziekenhuis
- Funding
(Source(s) of Monetary or Material Support)
St Antonius Hospital, Nieuwegein
- PublicationsN/A
- Brief summaryRationale:
Despite of the common preventive medication with calcium and magnesium, sixty to seventy percent of the patients treated with oxaliplatin for a colorectal carcinoma will suffer from an acute peripheral neuropathy. These complaints disable patients temporarily and therefore reduce their quality of live during the treatment with chemotherapy.

Objectives:
Main object: Is there a reduction of the acute peripheral neuropathy complaints of patients with advanced or metastatic colorectal cancer due to the infusion of heated oxaliplatin?
Does the quality of life of these patients improve?
Secondary object: The evaluation of the effectivity of the treatment.

Study design:
A pilot study in 15 patients.

Study population:
Patients treated adjuvant or palliative with oxaliplatin for a colon-rectal carcinoma who suffer from an acute peripheral neuropathy after the first treatment in het St. Antonius hospital of Nieuwegein/Utrecht (The Netherlands).

Intervention:
Oxaliplatin will be heated to a temperature of 36 degrees Celsius during the 2-hours infusion period, irrespective the standard prophylaxis with magnesium and calcium.

Main study parameters/endpoints:
Changes in the acute peripheral neuropathy complaints. Changes in quality of life (cancer related and symptom related) in the period after infusion of heated oxaliplatin in comparison with the period after infusion of oxaliplatin on roomtemperature.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness:
Before entering the study assessment of acute peripheral neuropathy will be carried out on two moments. If acute peripheral neuropathy is diagnosed, patients will enter the study. During the second, third and fourth cycle of the chemotherapeutical regime the Total Neuropathy Score examination will be carried out on three moments. If acute peripheral neuropathy is not diagnosed patients will not enter the study.
There is no physical risk or physiological discomfort to expect from the infusion of heated oxaliplatin.
- Main changes (audit trail)
- RECORD3-apr-2011 - 11-apr-2011


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl